Loading organizations...
Hydra Biosciences is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, focused on developing drugs to treat pain, inflammation, renal disease, anxiety, and pulmonary conditions through expertise in novel ion channels like Transient Receptor Potential (TRP) channels. The privately held company utilizes proprietary platforms to identify and advance drug candidates, such as the TRPA1 antagonist HX-100 for painful diabetic neuropathy. It secured $18.9 million in Series B funding in 2006 and has approximately 11 people listed in profiles. Hydra Biosciences generates revenue through research collaborations and license agreements, notably a worldwide partnership with Boehringer Ingelheim for TRP inhibitors targeting renal diseases. Russell Herndon serves as President and CEO. The company was incorporated in June 2001 by founders Laurie Keating, Mark Keating, David Clapham, and Dean Li.
Hydra Biosciences has raised $84.0M across 4 funding rounds.
Hydra Biosciences has raised $84.0M in total across 4 funding rounds.
Hydra Biosciences has raised $84.0M across 4 funding rounds. Most recently, it raised $22.0M Series D in January 2009.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Jan 1, 2009 | $22M Series D | — | Abingworth, Advanced Technology Ventures, Lightspeed Venture Partners, OrbiMed, Polaris Partners | Announced |
| Mar 1, 2008 | $34M Series C | — | Abingworth, Advanced Technology Ventures, Lightspeed Venture Partners, OrbiMed, Polaris Partners | Announced |
| Jan 1, 2004 | $19M Series B | — | Abingworth, Advanced Technology Ventures, Lightspeed Venture Partners, Longwood Fund, OrbiMed, Polaris Partners | Announced |
| Jul 1, 2002 | $9M Series A | — | Advanced Technology Ventures, Lightspeed Venture Partners, Longwood Fund, OrbiMed, Polaris Partners | Announced |
Hydra Biosciences has raised $84.0M in total across 4 funding rounds.
Hydra Biosciences's investors include Abingworth, Advanced Technology Ventures, Lightspeed Venture Partners, OrbiMed, Polaris Partners, Longwood Fund.
Hydra Biosciences is a biopharmaceutical company founded in 2001 and based in Cambridge, Massachusetts, specializing in developing small-molecule drugs targeting ion channels to treat pain, inflammation, anxiety, pulmonary diseases, and renal conditions.[1][2][3][4] It leverages proprietary platforms to identify drug candidates addressing unmet medical needs, raised $95.18M in funding, and reached clinical-stage development before undergoing an asset sale.[1][2] Key programs include TRPC4/TRPC5 inhibitors like HC-070 (Phase 1 for depressive disorder), TRPC6 antagonists like BI-749327 (preclinical for renal fibrosis), and earlier efforts like Z-212 (discontinued for pain) and TRPA1-targeted candidates for pain and asthma.[4] While no longer independently operational post-asset sale, its pipeline influenced subsequent therapies in ion channel modulation.[1]
Hydra Biosciences was established in 2001 in Cambridge, Massachusetts, as a privately held, clinical-stage biopharmaceutical venture focused on ion channel drug discovery.[1][2][3] Specific founders are not detailed in available records, but the company emerged during a biotech boom in ion channel therapeutics, building proprietary platforms to target proteins like TRPC4/5, TRPC6, Nav1.7/1.8, and TRPA1 for nervous system and inflammatory disorders.[1][4] Early traction came from raising $95.18M, advancing multiple candidates to preclinical and Phase 1 stages, including HC-070 and BI-749327, before culminating in an asset sale that transferred its portfolio to acquirers.[1][4] This marked a pivotal shift from independent R&D to integration into larger pharma ecosystems.
Hydra Biosciences rode the early-2000s wave of ion channel drug discovery, a trend amplifying post-2010 with validated targets like Nav1.7 for pain and TRP channels for inflammation, amid rising demand for non-opioid analgesics and fibrosis therapies.[1][4] Timing aligned with biotech clustering in Cambridge, fueling ecosystem growth through VC inflows and talent pipelines. Market forces like opioid crises and chronic disease prevalence (e.g., anxiety, pulmonary issues) favored its pipeline, influencing acquirers to advance TRPC/TRPA1 assets into modern portfolios. It contributed to the biotech startup ecosystem by validating ion channel platforms, paving the way for follow-on innovations in precision neurology and rare diseases.
Post-asset sale, Hydra's legacy endures through acquired programs like TRPC inhibitors, potentially reemerging in big pharma trials amid trends in non-addictive painkillers and AI-driven target validation.[1][4] Rising fibrosis and mental health burdens, plus advances in cryo-EM for ion channels, position its tech for revival—watch for Phase 2 data on HC-070 analogs or TRPC6 expansions. Its influence may evolve via ecosystem integration, underscoring how nimble biotechs like Hydra seed enduring platforms in the $100B+ neuro/inflammatory market, tying back to its core mission of unmet-need innovation.[1][2][4]
